Pulmonary Arterial Hypertension Market by Drugs (ERA, Prostacyclin and Prostacyclin Analogs, sGC Stimulators, and pde-5 Dipsticks), Type (Branded and Generics), Route of Administration (Oral, Intravenous/ Subcutaneous, and Inhalational): Global Market Size Estimates and Forecast (2022-2030)

Code: BMIRE00026858 | Pages: 100 | Industry: Pharmaceuticals | Date: Oct 2022 | Type: Global

The market crossed US$ 7.83 billion in 2022 and is expected to hit US$ 12.36 billion by 2030, recording a CAGR of 5.89% during the forecast period

The market has been significantly growing due to the high prevalence of pulmonary arterial hypertension

Pulmonary arterial hypertension (PAH) is a rare, progressive infection indicated by high blood pressure (hypertension) in the arteries of the lungs (pulmonary artery) for no evident reason. The increasing prevalence of pulmonary arterial hypertension is fueling the market. For instance, as per the National Organization for Rare Disorders, Inc. (NORD), PAH frequency is higher in females than males, i.e., 3-5 times higher. It tends to impact females between the ages of 30 and 60. In the US, new cases are estimated to occur in one to two individuals per million each year and approximately 500-1000 new cases of PAH are diagnosed yearly. The incidence trend is estimated to be similar in Europe.

Within the report, the market is segmented into drugs, type, route of administration, and geography. Based on drugs, the global pulmonary arterial hypertension market is segmented into ERA, prostacyclin and prostacyclin analogs, sGC stimulators, and pde-5 dipsticks. Based on type, the market is bifurcated into branded and generics. Based on the route of administration, the market segmentation is oral, intravenous/ subcutaneous, and inhalational. Geographically, the market is sub-segmented into North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa.

Entry of generics drugs will empower growth over the forecasted period

Generic drugs are a keyway to reduce overall healthcare costs. In May 2019, Teva Pharmaceutical Industries launched a generic version of Gilead’s Letairis (ambrisentan) Tablets, 5 mg, and 10 mg, in the United States. Ambrisentan is an endothelin receptor antagonist for treating pulmonary arterial hypertension (PAH) (WHO Group 1) to improve activity and delay clinical worsening.

The prostacyclin and prostacyclin segment is the growing segment due to high demand and growing indications

The key factors contributing to the large share include growing FDA approvals and growing applications. In March 2022, United Therapeutics Corporation announced the U.S. FDA approval of Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) to improve exercise ability. Tyvaso DPI symbolizes a new formulation and inhalation device for inhaled treprostinil and is the only dry powder inhaler approved by the FDA for use in PAH and PH-ILD. It is the easiest way for patients to administer a prostacyclin. Moreover, in June 2021, Johnson & Johnson announced U.S. Food and Drug Administration (FDA) approval for UPTRAVI (selexipag) injection for intravenous use to treat pulmonary arterial hypertension in adult patients with WHO functional class II-III for patients who cannot take oral medicine. Selexipag is a selective prostacyclin IP receptor agonist.

Recent strategic developments in the pulmonary arterial hypertension market

The pulmonary arterial hypertension market has undergone several significant developments, and a few of these have been mentioned below:

  • In February 2022, Germany’s Bayer launched Saudi Arabia’s first “digital hub” to enhance the management of pulmonary hypertension (PH). The AAN Digital Hub addresses gaps in diagnosing and treating the disease during the COVID-19 pandemic. They focus on facilitating virtual referrals for patients and enabling learning exchange between primary physicians, specialists, and their patients.
  • In April 2021, United Therapeutics Announced FDA Approval and the Launch of Tyvaso for treating Pulmonary Hypertension Associated with Interstitial Lung Disease. It is the first and only therapy in the United States for patients with PH-ILD, a serious, life-threatening disease with potentially more than 30,000 patients in need.

The pulmonary arterial hypertension market is driven by several players by implementing strategic activities such as investments, new launches, mergers & acquisitions, and partnerships. Actelion Pharmaceutical Ltd; Gilead Sciences, Inc; United Therapeutics Corporation; Bayer Healthcare; Pfizer, Inc.; Novartis International AG; GlaxoSmithKline plc; Arena Pharmaceuticals; Merck Sharp & Dohme Corp; and Dong-A ST Co., Ltd are among the prominent players operating in the market.

The target audience for the report:

  • Raw Material Providers
  • Associations, Organizations, Forums, And Alliances
  • Government Bodies, Such as Regulating Authorities and Policymakers
  • Hospitals
  • Clinics
  • Venture Capitalists, Private Equity Firms, and Start-Up Companies
  • Research Institutes, Organizations, and Consulting Companies

Scope of the report:

In this report, the market has been segmented based on:

  • Drugs:
  • ERA
  • Prostacyclin and Prostacyclin Analogs
  • sGC Stimulators
  • pde-5 Dipsticks
  • Type:
    • Branded
    • Generics
  • Route of Administration:
    • Oral
    • Intravenous/ Subcutaneous
    • Inhalational
  • Region:
    • North America
    • Europe
    • Asia Pacific
    • South & Central America
    • Middle East & Africa
  • Companies Profiled
    • Actelion Pharmaceutical Ltd
    • Gilead Sciences, Inc
    • United Therapeutics Corporation
    • Bayer Healthcare
    • Pfizer, Inc
    • Novartis International AG
    • GlaxoSmithKline plc
    • Arena Pharmaceuticals
    • Merck Sharp & Dohme Corp
    • Dong-A ST Co., Ltd

The List of Companies
- Actelion Pharmaceutical Ltd
- Gilead Sciences, Inc
- United Therapeutics Corporation
- Bayer Healthcare
- Pfizer, Inc
- Novartis International AG
- GlaxoSmithKline plc
- Arena Pharmaceuticals
- Merck Sharp & Dohme Corp
- Dong-A ST Co., Ltd

Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$2000
Site License
$3000
Enterprise License
$4000